GRTS
Gritstone Oncology IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$3.80M
P/E Ratio
—
EPS
$-1.09
Beta
0.50
52W High
$0.00
52W Low
$0.00
50-Day MA
$0.32
200-Day MA
$1.01
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Gritstone Oncology Inc
Gritstone bio, Inc., a clinical-stage biotechnology company, is dedicated to developing tumor-specific cancer immunotherapies to combat various types of cancer and infectious diseases. The company is headquartered in Emeryville, California.
Fundamentals
| Revenue (TTM) | $14.61M |
| Gross Profit (TTM) | $-91.46M |
| EBITDA | $-129.23M |
| Operating Margin | -2995.00% |
| Return on Equity | -201.90% |
| Return on Assets | -46.70% |
| Revenue/Share (TTM) | $0.12 |
| Book Value | $0.19 |
| Price-to-Book | 0.21 |
| Price-to-Sales (TTM) | 0.26 |
| EV/Revenue | 103.91 |
| EV/EBITDA | -0.91 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -52.90% |
| Shares Outstanding | $118.11M |
| Float | $115.44M |
| % Insiders | 1.91% |
| % Institutions | 29.03% |
Data last updated: 4/8/2026